- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM - ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback